May. 11 at 11:07 AM
$MYGN
The sales force expansion is tactical "pre-scaling" for the
$5B Precise MRD market. You must hire 6 months early to educate physicians. At a 0.46x sales valuation, the market treats this team as a liability rather than a growth engine.
The "invisible" inflection point is the April Cigna deal. It wasn't in Q1. Because the infrastructure is already fixed, this revenue has massive flow-through to margins starting now.
H2 2026 is a product "super-cycle": FirstGene, AI-Prolaris, and Precise MRD are all scaling at once. This drives the "operating leverage" needed to hit the
$37M–
$49M EBITDA target.
Insider buying is a high-conviction signal. Execs see internal access data and physician feedback before it hits GAAP. With ~
$199M in liquidity, MYGN is fully funded to bridge this gap. If they hit
$100M+ FCF, the current "distressed" price is a coiled spring.
Why do you think there has been so much recent insider buying…they know this
